GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neoleukin Therapeutics Inc (NAS:NLTX) » Definitions » 50-Day SMA

Neoleukin Therapeutics (Neoleukin Therapeutics) 50-Day SMA : $13.87 (As of May. 03, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Neoleukin Therapeutics 50-Day SMA?

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2024-05-03), Neoleukin Therapeutics's 50-Day SMA is $13.87. It's 20-Day SMA is $13.79 and 200-Day SMA is $N/A.


Competitive Comparison of Neoleukin Therapeutics's 50-Day SMA

For the Biotechnology subindustry, Neoleukin Therapeutics's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neoleukin Therapeutics's 50-Day SMA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neoleukin Therapeutics's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Neoleukin Therapeutics's 50-Day SMA falls into.



Neoleukin Therapeutics  (NAS:NLTX) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neoleukin Therapeutics  (NAS:NLTX) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.


Neoleukin Therapeutics 50-Day SMA Related Terms

Thank you for viewing the detailed overview of Neoleukin Therapeutics's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.


Neoleukin Therapeutics (Neoleukin Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
188 East Blaine Street, Suite 450, Seattle, WA, USA, 98102
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Executives
Baker Bros. Advisors Lp 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Sean Michael Smith officer: Principal Accounting Officer C/O NEOLEUKIN THERAPEUTICS, INC., 188 E. BLAINE STREET, SUITE 450, SEATTLE WA 98102
Priti Patel officer: Chief Medical Officer C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE WA 98102
Erin Lavelle director C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Donna Cochener officer: General Counsel, SVP Legal C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, SUITE 450, SEATTLE WA 98102
Rohan Palekar director 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Jonathan G Drachman director, officer: See Remarks 21823 30TH DRIVE SE, BOTHELL WA 98021
Carl Walkey officer: Senior Vice President C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Robert Ho officer: Chief Financial Officer 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Holly Vance officer: General Counsel C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE E., SEATTLE WA 98102
Martin Babler director C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Erin M. Lavelle director 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Jeremy Green 10 percent owner 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080

Neoleukin Therapeutics (Neoleukin Therapeutics) Headlines

From GuruFocus